(Source: Threshold Pharmaceuticals Inc) Threshold Pharmaceuticals Reports Fourth Quarter and Year End 2012 Financial and Operational Results SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 03/07/13 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today reported financial results for the fourth quarter and year ended December 31, 2012 and provided a clinical outlook related to the development of TH-302, the company's lead investigational hypoxia-targeted drug currently in pivotal Phase 3 clinical studies for both soft tissue sarcoma and pancreatic cancer. Revenue for the fourth quarter and year ended December 31, 2012 was $2.0 million and $5.9 million, respectively. Net income for the fourth...
0 Responses to Threshold Pharmaceuticals Reports Fourth Quarter and Year End 2012 Financial and Operational Results (Threshold Pharmaceuticals Inc)